Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Clinical Evaluation of Customized Attachment Composites in Clear Aligner Therapy

NCT07261735 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2025-08-25
Last updated
2026-09-22

Condition(s) studied

Clear Aligner TherapyAligner Attachment Wear

Investigational drug(s) / intervention(s)

GC G-ænial A'Chord Universal CompositeSpectra ST HV (High Viscosity)Spectra ST LV (Low Viscosity)GC Aligner Connect Composite

GC G-ænial A'Chord Universal Composite: Universal composite resin used as the control material for attachment reproduction.

Spectra ST HV (High Viscosity): High-viscosity universal composite resin clinically used for clear aligner attachment reproduction.

Spectra ST LV (Low Viscosity): Low-viscosity universal composite resin clinically used for clear aligner attachment reproduction.

GC Aligner Connect Composite: Customized composite resin specifically developed for clear aligner attachments.

Study summary

This prospective observational clinical study aims to evaluate the three-dimensional surface wear and clinical survival of orthodontic attachments fabricated with customized composite materials used in clear aligner therapy. Attachments play a critical role in the biomechanical efficiency of aligner treatment by facilitating planned tooth movements. However, the mechanical and surface properties of the composites used for attachment fabrication may affect their wear behavior and long-term stability.

In this study, four different composite materials will be tested using a split-mouth design in patients treated with clear aligners. Each quadrant will receive a different composite, including both customized and universal types. All attachments will be fabricated using standardized digital templates and bonded under identical clinical conditions. Surface wear will be evaluated using three-dimensional optical scanning and metrology software at baseline, 1 week, 1 month, 3 months, and 6 months. Lost attachments will be replaced and recorded but excluded from wear analysis.

The results of this study are expected to provide valuable insights into the optimal material selection for clear aligner attachments, improving treatment accuracy and clinical durability.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Fully erupted permanent dentition. * No existing prosthetic restorations. * Mild-to-moderate dental crowding or spacing (2-6 mm). * Patients who are scheduled to undergo clear aligner therapy at the Department of Orthodontics, Gülhane Faculty of Dentistry, between 01.08.2025 and 01.08.2026. * Patients who agree to participate and provide informed consent. Exclusion Criteria: * History of previous fixed orthodontic treatment. * Patients with poor predicted compliance or low cooperation. * Presence of severe or generalized periodontal disease. * High caries incidence or untreated caries. * Poor oral hygiene * Habitual consumption of hard foods. * Bruxism * Congenitally missing permanent teeth. * Dental developmental anomalies. * Teeth with existing composite resin restorations or ceramic crowns on buccal surfaces (which may interfere with attachment bonding or wear analysis)

Primary outcome measure(s)

  • 3D Surface Wear of Orthodontic Attachments — Baseline to 6 months
    The three-dimensional surface wear of attachments will be evaluated using Zeiss Inspect software (Zeiss GmbH) by comparing baseline (T0) and follow-up scans (T1: 1 week, T2: 1 month, T3: 3 months, T4: 6 months). Wear will be quantified as total surface deviation (sigma) across the entire attachment surface and as point deviations measured at predefined corner and mid-surface points. All 3D alignments and analyses will be performed by an independent, blinded examiner who is unaware of the composite allocation for each quadrant.

Trial sites (1)

FacilityCityRegionStatus
University of Health Sciences, Gülhane Faculty of Dental Medicine Ankara Ankara Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07261735 on ClinicalTrials.gov ↗ ← All trials in Turkey